Breast cancer is one of the most common diseases and is the first cause of cancer-related deaths among women worldwide. Generally, late detection of breast cancer symptoms leads to higher mortality rates. Thus, early diagnosis of breast cancer is impe...
Breast cancer is one of the most common diseases and is the first cause of cancer-related deaths among women worldwide. Generally, late detection of breast cancer symptoms leads to higher mortality rates. Thus, early diagnosis of breast cancer is imperative to boost patient’s survival rate. Traditional diagnostic methods such as RT-qPCR take a long time, making it less suitable for on-site diagnosis.
Herein, we developed a CRISPR-Based SERS biosensor for an early on-site diagnosis of breast cancer targeting miRNA-511, one of the biomarkers for breast cancer. The synergy of SERS and CRISPR/Cas technologies has further enhanced the selectivity and sensitivity of miRNA-511 detection. In this work, alloy gold-nickel-gold nanorods (Au-Ni-Au NRs) were first electrochemically deposited onto an anodic aluminum oxide (AAO) mask to be used as the nanomaterial probe. Consequently, CRISPR/Cas13 becomes activated upon its addition in the presence of target RNA via its binding to crRNA, allowing for a sensitive detection.
Accordingly, leveraging the integration of CRISPR and SERS technologies, this study presents a biosensor capable of rapidly detecting breast cancer biomarkers on-site, removing the need for complex amplification steps and simplification on the experimental process. Therefore, our developed biosensor offers the potential for detecting other biomarkers beyond breast cancer disease that can be highly useful in developing countries and in field settings where medical infrastructures is limited.